RxDoctor Payments Data

Luis Anglo, MD

Urology · Saint Louis, MONPI 1437112547

Payments from drug & device makers

$5,976in general payments, 2019–2025

Across 301 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$892
  • Procept Biorobotics Corporation$752
  • Astellas Pharma US Inc$547
  • Myriad Genetic Laboratories, Inc.$498
  • Boston Scientific$481
  • Rochester Medical Corporation$386
  • plus $2K from 35 others

What the payments were for

  • Travel & lodging$2204%
  • Food & beverage$5,73296%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,976 in reported general payments places this provider in the 60th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$114,790
Medicare patients
331
Services billed
1,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron27$24,070
GemtesaVibegron22$14,157
Alfuzosin Hcl ErAlfuzosin Hcl160$3,805
Tamsulosin Hcl349$3,455
Finasteride240$2,559
Potassium Citrate ErPotassium Citrate16$1,649
Bethanechol Chloride32$1,309
Naloxone Hcl13$827
Cefdinir54$604
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst46$578
CefuroximeCefuroxime Axetil105$391
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen129$372
Cephalexin116$357
Allopurinol21$206
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim96$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$547$24,07027 claims
Sumitomo Pharma America, Inc.Gemtesa$40$14,15722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 urology providers in Missouri.

Other urology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →